Cytosorbents (CTSO) Accumulated Expenses (2010 - 2026)

Cytosorbents has reported Accumulated Expenses for 17 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 91.18% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (up 91.18% YoY), and the FY2025 full-year result was $3.4 million, up 1141.09% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $6.0 million, up from $3.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $9.4 million in Q1 2022, with the low at $275000.0 in Q4 2024.
• Historically, Accumulated Expenses has averaged $5.8 million across 5 years, with a median of $6.3 million in 2023.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 1142.37% — and 2024, when it plunged 96.26%.
• Cytosorbents' Accumulated Expenses stood at $592398.0 in 2022, then surged by 1142.37% to $7.4 million in 2023, then sank by 96.26% to $275000.0 in 2024, then soared by 1141.09% to $3.4 million in 2025, then surged by 74.63% to $6.0 million in 2026.
• The last three Accumulated Expenses figures came in at $6.0 million (Q1 2026), $3.4 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.